Entrada launches today, taking a $59M shot at some tough intracellular targets
Earlier this year, Ohio State singled out Professor Dehua Pei for the commercial promise he’d demonstrated for his work, praising his work involving the “discovery of a family of small cyclic peptides that are exceptionally potent in cell-penetrating, capable of delivering all major drug modalities — from small molecules to large nucleic acids — into the cell with unprecedented efficiencies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
